Switzerland

Reporting serious allegations made against the WIPO director general was not fake news, it was essential

The agency's outgoing head Francis Gurry has hit out at media coverage of complaints made against him by his deputy, but the real problem was a total lack of transparency in how the affair was handled Read more

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

WIPO assembly chair calls in central UN unit to investigate the explosive claims against DG Francis Gurry

Päivi Kairamo, chair of WIPO’s General Assemblies, has asked the United Nations’ Organisation of Internal Oversight Services (OIOS) to investigate the claims made by James Pooley, the former deputy director general of the organisation, in a Report…

The case for IP can only be fully made if its institutions are transparent and subject to independent oversight

With intellectual property under more scrutiny than it has ever been before, problems at three of the world’s top IP agencies could not have occurred at a worse time. The major controversies besetting both the European Patent Office and the World…

It's not all doom and gloom for pharmaceutical innovators in India

Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet … Read more

Reporting serious allegations made against the WIPO director general was not fake news, it was essential

The agency's outgoing head Francis Gurry has hit out at media coverage of complaints made against him by his deputy, but the real problem was a total lack of transparency in how the affair was handled Read more

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

China and South Korea will displace the West as the world’s innovation leaders by 2029

New report claims status of US, EU and UK as leading innovators under threat as they struggle to maximise return on R&D investment. Read more

Gurry investigation dropped by WIPO member states; transparency and accountability are the losers - UPDATE

This blog was updated on 12th October to include new information about the vote that took place in Geneva on 7th October and to provide links to further documents that have been made public, including what is said to be an unredacted copy of the…

Life sciences battlefields – hot litigation topics in Switzerland

This chapter aims to give a brief overview of the patent litigation system in Switzerland and highlight some current trends in life sciences patent litigation. Read more

Sisvel in the firing line after u-blox launches US FRAND suit

In echoes of its previous InterDigital litigation, the auto component manufacturer turns again to US district court, accusing licensing business of seeking ”unreasonable royalty rates” Read more

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

Recent developments in Swiss patent and trademark practice

Court developments In Switzerland, the Federal Patent Court is exclusively competent for patent infringement and validity cases. The number of cases handled by the court has remained relatively constant over the past three years. In its annual… Read more

Revealed: the billions to be spent on patent renewals in 2021 and beyond

Samsung on the hook for over $135 million this year alone, with China's national IP office and the USPTO set to pull in $100 billion over lifetime of all their active grants Read more

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

China and South Korea will displace the West as the world’s innovation leaders by 2029

New report claims status of US, EU and UK as leading innovators under threat as they struggle to maximise return on R&D investment. Read more

WIPO staff council legal rep demands immediate removal of Gurry after distribution of misconduct report - UPDATE

This blog has been updated to include additional material relating to the report compiled by the UN's Office of Internal Oversight Services following its investigation into alleged misconduct by WIPO DG Francis Gurry. 

The legal counsel to…

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

Sisvel in the firing line after u-blox launches US FRAND suit

In echoes of its previous InterDigital litigation, the auto component manufacturer turns again to US district court, accusing licensing business of seeking ”unreasonable royalty rates” Read more

Reporting serious allegations made against the WIPO director general was not fake news, it was essential

The agency's outgoing head Francis Gurry has hit out at media coverage of complaints made against him by his deputy, but the real problem was a total lack of transparency in how the affair was handled Read more

Revealed: the billions to be spent on patent renewals in 2021 and beyond

Samsung on the hook for over $135 million this year alone, with China's national IP office and the USPTO set to pull in $100 billion over lifetime of all their active grants Read more

Sisvel in the firing line after u-blox launches US FRAND suit

In echoes of its previous InterDigital litigation, the auto component manufacturer turns again to US district court, accusing licensing business of seeking ”unreasonable royalty rates” Read more

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

Revealed: the billions to be spent on patent renewals in 2021 and beyond

Samsung on the hook for over $135 million this year alone, with China's national IP office and the USPTO set to pull in $100 billion over lifetime of all their active grants Read more

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

MIT and Harvard lead the world’s research institutions in patent quality, but look out for the rise of China

The research centres which produce the most world-leading assets are currently found in the US and Europe, but analysis shows that Chinese universities are beginning to catch up(Picture: MIT) Read more

Novartis is the latest Big Pharma player to extend olive branch in Third World patent rights row

While the global quarrel over the pricing of patented drugs continues unabated, Swiss pharmaceutical giant Novartis has announced that it will offer a number of its medicines at significant discount to developing countries.

According to a press…

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

MIT and Harvard lead the world’s research institutions in patent quality, but look out for the rise of China

The research centres which produce the most world-leading assets are currently found in the US and Europe, but analysis shows that Chinese universities are beginning to catch up(Picture: MIT) Read more

Novartis is the latest Big Pharma player to extend olive branch in Third World patent rights row

While the global quarrel over the pricing of patented drugs continues unabated, Swiss pharmaceutical giant Novartis has announced that it will offer a number of its medicines at significant discount to developing countries.

According to a press…

It's not all doom and gloom for pharmaceutical innovators in India

Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet … Read more

Reporting serious allegations made against the WIPO director general was not fake news, it was essential

The agency's outgoing head Francis Gurry has hit out at media coverage of complaints made against him by his deputy, but the real problem was a total lack of transparency in how the affair was handled Read more

US lawmakers sound alarm on China’s WIPO ambitions

China has nominated agency insider Wang Binying for the director general post, but the US is said to favour Singapore's candidate Read more

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more

The case for IP can only be fully made if its institutions are transparent and subject to independent oversight

With intellectual property under more scrutiny than it has ever been before, problems at three of the world’s top IP agencies could not have occurred at a worse time. The major controversies besetting both the European Patent Office and the World…

Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation

Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more